A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93% of pediatric patients tested. Most cancer drugs are targeted to specific organs or locations in the body. Larotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in…
Visited 1 times, 1 visit(s) today
